While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market

Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.

Amgen sign at biopharmaceutical company campus in Silicon Valley, biotech company headquartered in Thousand Oaks - South San Francisco, CA, USA - 2020
Amgen's sotorasib is filed with the US FDA; tezepelumab is being prepared for filings • Source: Shutterstock

Amgen, Inc. entered 2021 with two new high-profile potential additions to its commercial portfolio – sotorasib for non-small cell lung cancer patients with KRAS G12C mutations and tezepelumab for severe asthma. But while Amgen executive vice presidents David Reese and Murdo Gordon are looking forward to bringing these therapies to market in the next year or so, COVID-19 impacts on sales and competitive pressures remain near-term headwinds to the company’s growth.

Scrip spoke with Reese, EVP of research and development, and Gordon, EVP of global commercial operations, about pivotal data, filing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?